Cue Biopharma reports Q1 2024 net loss $12.3M, cash $41M into Q1 2025

Cue Biopharma, Inc.

2024-Q1 EPS reported -$0.25 revenue$1,717,000

Collaboration revenue $1.7M vs $0.2M YoY; net loss $0.25/share vs $0.29.
Cash and equivalents $41.0M at March 31, expected to fund operations into Q1 2025.
CUE-101 abstract accepted for oral presentation at ASCO 2024; FDA meeting on registrational path.
Preclinical CUE-401 (with Ono) and new CUE-500 series for autoimmune/inflammatory diseases.
R&D expenses $10.2M, G&A $4.2M; net loss $12.3M for the quarter.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cue Biopharma, Inc. reported first quarter 2024 results: revenue $1.7 million, net income Net loss $(12.3) million, EPS $(0.25) per share.

Period: first quarter 2024
Revenue: $1.7 million
Net income: Net loss $(12.3) million
EPS: $(0.25) per share
Result: reported results

Exact text from the filing

disease positions us well to potentially deliver value creation for our shareholders.” First Quarter 2024 Financial Results The Company reported collaboration revenue of $1.7 million and $0.2 million for the three months ended March 31, 2024 and 2023, respectively. The increase was due to revenue earned from our Collaboration and Option Agreement with Ono

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

Cue Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-056848

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.